Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration - Quiz - MDSpire

Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration

  • By

  • Hongyang Zhang

  • Rui Yang

  • Yu Ma

  • Jiahui Yang

  • Binyan Yang

  • Lingdi Dong

  • Nan Yu

  • April 24, 2026

  • 0 min

Share

Original Source(s)

Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration

  • by Hongyang Zhang, Rui Yang, Yu Ma, Jiahui Yang, Binyan Yang, Lingdi Dong, Nan Yu

  • April 24, 2026

Related Content

Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation

Cupping vs UVB: Comparable Psoriasis Outcomes?

Randomized study found no statistically significant differences in disease improvement between treatments over 8 weeks.

Investigating the Therapeutic Mechanisms and Key Bioactive Compounds of Solanum nigrum in Treating Psoriatic Lesions